Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein–induced acute lung injury
Pavel A. Solopov, Ruben Manuel Luciano Colunga Biancatelli, Elizabeth R. Sharlow, John S. Lazo, John D. Catravas · 2026
Read Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein–induced acute lung injury by Pavel A. Solopov, Ruben Manuel Luciano Colunga Biancatelli, Elizabeth R. Sharlow, John S. Lazo, John D. Catravas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13327958.txt.
Description
Pavel A Solopov and co-authors test a phosphatase blocker against alcohol-amplified lung injury in mice in a 2026 study. Heavy drinking raises the risk of severe lung failure, and the COVID-19 spike protein alone can injure lungs, worse still in alcohol-fed animals. The drug KVX-053 blocks PTP4A3, a regulator of inflammation and vessel leak.
Mice on alcohol diets showed more white cells and protein leakage in lung wash fluid after spike exposure, plus higher IL-6, TNF-α, and TGF-β signals. Daily KVX-053 for three days blunted each of those changes, restoring barrier tightness and quieting the NF-κB, STAT3, and inflammasome pathways. The target looks druggable for drinkers facing severe lung insults.
Catalog record
| CREATOR | Pavel A. Solopov, Ruben Manuel Luciano Colunga Biancatelli, Elizabeth R. Sharlow, John S. Lazo, John D. Catravas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44361 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |